Stocks · News reference
Filed: 2026-09-29 AccNo: 0001104659-26-111952 Size: 221 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 9.01: Financial Statements and Exhibits
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
The Phase IIA part of the clinical trial is designed to evaluate different dosage regimens of the oral gummies for the treatment of different severity levels of the Ebola Bundibugyo virus infection and disease in the
NanoViricides, Inc. (NYSE:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, herewith provides additional details on its Phase II Clinical Trial of NV-387 Oral
Nanoviricides (AMEX:NNVC) reported quarterly losses of $(0.10) per share which met the analyst consensus estimate. This is a 23.08 percent increase over losses of $(0.13) per share from the same period last year.